Codivir is based on a short peptide chain of 16 synthetic amino acids, derived from HIV-1 integrase. It was first discovered by researchers at Hebrew University. This drug was originally studied to kill HIV cells.
In the trial, patients received 2 injections of Codivir/day for 10 days and tested every other day.
Professor Shlomo Maayan, head of the infectious diseases department at Barzilai Medical Center in Israel, said that five out of 12 patients treated with the drug had a significantly reduced viral load. Codivir suppressed viral replication in all patients within 3 days of being treated.
The phase two trial will involve 150 patients and is expected to begin next month. According to Zyon Ayni, general manager of Code Pharma, the next goal is to complete the trial within about 3-6 months and then apply for an emergency use authorization for the drug Codivir.